(2024). Adagrasib in KRYSTAL-12 has Not Broken the KRAS G12C Enigma Code of the Unspoken 6-Month PFS Barrier in NSCLC. Lung Cancer: Targets and Therapy.
Successfully copied to clipboard
Copying to clipboard failed
Chicago Style (17th ed.) Citation
"Adagrasib in KRYSTAL-12 Has Not Broken the KRAS G12C Enigma Code of the Unspoken 6-Month PFS Barrier in NSCLC."
Lung Cancer: Targets and Therapy 2024.
Successfully copied to clipboard
Copying to clipboard failed
MLA (9th ed.) Citation
"Adagrasib in KRYSTAL-12 Has Not Broken the KRAS G12C Enigma Code of the Unspoken 6-Month PFS Barrier in NSCLC."
Lung Cancer: Targets and Therapy, 2024.
Successfully copied to clipboard
Copying to clipboard failed
Warning: These citations may not always be 100% accurate.